what is glp 1 agonist drugs Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment Top GLP-1 Agonists Balance Weight

In obese patients, acipimox can inhibit adipose tissue lipolysis by activating protein upregulated in macrophage by INF- (PUMA-G) (also known as the hydroxycarboxylic acid receptor 2 [HCA2] and GPR109a) receptors

doi: 10.3390/cimb45080392 [DOI] [PMC free article] [PubMed] [Google Scholar] 16

These strategies compared to currently available drug medications such as thiazolidinediones, sulphonylureas, and insulin, have the potential to treat diabetes without causing side effects of hypoglycemia and weight gain

Unfortunately, more than 50 percent of people who start GLP-1 drugs quit after one year most likely due to its side effects (1)

25,26 Effects on Epicardial Adipose Tissue GLP1-RAs decrease the volume of epicardial adipose tissue, which is often elevated in HFpEF and is a source of proinflammatory cytokines and adipokines

Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]